Explore

Study Suggests GLP-1 Medications May Lower Breast Cancer Risk in Overweight Women

Study Suggests GLP-1 Medications May Lower Breast Cancer Risk in Overweight Women

A recent study published in the JCO Oncology Practice journal indicates that GLP-1 medications, commonly used for weight loss, may be linked to a reduced risk of developing breast cancer. The study analyzed health records from over 111,000 women aged 45 to 80 within the University of Pennsylvania Health System. These women were either overweight or obese, and the study aimed to observe who developed breast cancer over several years. The findings suggest that women using GLP-1 medications had a 30% lower risk of developing breast cancer. Dr. Tara Narula, ABC News chief medical correspondent, explained that GLP-1s might reduce breast cancer risk by decreasing weight, inflammation, and improving insulin sensitivity. However, the study's lead author, Dr. Elizabeth McDonald, emphasized that the findings are observational and do not definitively confirm a causal relationship. The study adds to existing research suggesting the potential of GLP-1s as cancer prevention tools.

Study Finds GLP-1 Drugs May Reduce Breast Cancer Risk by 30%

Study Finds GLP-1 Drugs May Reduce Breast Cancer Risk by 30%

A study from the University of Pennsylvania's Perelman School of Medicine has found that women taking GLP-1 medications, commonly used for weight loss, are 30% less likely to develop breast cancer. The analysis involved over 110,000 women aged 45 to 80, revealing that these drugs, while not originally designed for cancer therapy, affect pathways associated with cancer development. The findings suggest potential for GLP-1 drugs as preventive treatments for high-risk women, although further clinical trials are needed to confirm their efficacy in cancer prevention.

Studies Indicate Weight-Loss Drugs May Reduce Breast Cancer Risk by 30%

Studies Indicate Weight-Loss Drugs May Reduce Breast Cancer Risk by 30%

Recent studies presented at the American Society of Clinical Oncology's annual meeting suggest that weight-loss drugs, specifically GLP-1 medications, may significantly reduce the risk of developing or dying from breast cancer. These drugs, originally used to treat type 2 diabetes and now widely used for weight management, have shown promising results in cancer prevention. One study involving 110,000 women found that those taking GLP-1 medications were 30% less likely to develop breast cancer. Another study indicated that adding these drugs to standard breast cancer treatment reduced the risk of death by 30%. Additionally, research involving patients with various cancers, including breast, lung, bowel, and liver, showed that those on weight-loss drugs were up to 50% less likely to have their disease progress to stage four.

Study Finds Ozempic-like Drugs May Reduce Breast Cancer Risk by 30%

Study Finds Ozempic-like Drugs May Reduce Breast Cancer Risk by 30%

A recent study from the University of Pennsylvania's Perelman School of Medicine suggests that women taking GLP-1 medications, such as Ozempic, are 30% less likely to develop breast cancer. These drugs, primarily used for weight loss, have shown potential benefits beyond their intended use, including reducing the risk of obesity-related cancers. The study analyzed data from over 110,000 women aged 45 to 80, finding a significant correlation between GLP-1 drug use and a decreased incidence of breast cancer. While the findings are promising, they do not establish a direct causal link, prompting calls for further clinical trials to explore the potential of these medications as preventative treatments for high-risk women.

GLP-1 Drugs Show Potential in Reducing Cancer Risk and Enhancing Treatment Outcomes

GLP-1 Drugs Show Potential in Reducing Cancer Risk and Enhancing Treatment Outcomes

Recent studies presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago have highlighted the potential of GLP-1 drugs, such as Ozempic, Wegovy, and Mounjaro, in reducing cancer risk and improving treatment outcomes. These drugs, initially used for diabetes and weight loss, are now being investigated for their effects on cancer. Research indicates that individuals taking GLP-1 medications may have lower rates of certain cancers, including breast cancer, and may experience slower disease progression. The studies suggest that GLP-1 drugs might act independently of weight loss by reducing inflammation and altering metabolic pathways involved in cancer development.

Penn Medicine Research Suggests Weight Loss Drugs May Prevent Breast Cancer

Penn Medicine Research Suggests Weight Loss Drugs May Prevent Breast Cancer

Preliminary research from Penn Medicine indicates that popular weight loss drugs, including Ozempic and Wegovy, may have the potential to prevent breast cancer. The study, led by Penn Medicine researchers, suggests that these medications could play a role in reducing breast cancer risk, although the exact mechanisms remain unclear. The research is still in its early stages, and while the findings are promising, they require further investigation to confirm the potential benefits and understand how these drugs might contribute to cancer prevention.

Exclusive-Cigna drops coverage of GLP-1 obesity drugs for its own employees

Exclusive-Cigna drops coverage of GLP-1 obesity drugs for its own employees

By Amina Niasse NEW YORK, June 2 (Reuters) - Health insurer Cigna will stop covering GLP-1 weight-loss drugs including Novo Nordisk's Wegovy and Eli Lilly's Zepbound in its employee health plan effective July 1, according to materials viewed by Reuters on Tuesday.

GLP-1 drugs may have a beneficial effect across many types of cancer

GLP-1 drugs may have a beneficial effect across many types of cancer

By Nancy Lapid June 3 (Reuters) - A growing body of evidence suggests that popular GLP-1 drugs, widely used for weight loss and diabetes, can provide protection against many types of cancer.

Study Links GLP-1 Medications to Lower Breast Cancer Risk in Women

Study Links GLP-1 Medications to Lower Breast Cancer Risk in Women

A large retrospective study has found that women using GLP-1 medications, typically prescribed for type 2 diabetes and obesity, have a significantly lower risk of developing breast cancer. The study analyzed health records of nearly 112,000 women aged 45 to 80 with a BMI of 25 or higher, revealing that those on GLP-1s were up to 35% less likely to be diagnosed with breast cancer. The research suggests that weight loss and metabolic changes associated with GLP-1 use may contribute to this reduced risk. However, the study only shows an association, not causation, and further research is needed to understand the mechanisms behind this link.

Telehealth Expansion Raises Concerns Over GLP-1 Drug Safety and Oversight

Telehealth Expansion Raises Concerns Over GLP-1 Drug Safety and Oversight

The surge in telehealth services has led to increased accessibility to GLP-1 medications, commonly used for weight loss, but has also raised significant safety concerns. Karleigh McClain, a compliance consultant from Tennessee, experienced severe side effects after receiving a high dosage of a GLP-1 drug prescribed via telehealth. This incident highlights the broader issue of medication errors associated with telehealth prescriptions. The expansion of telehealth, initially intended to improve healthcare access during the COVID-19 pandemic, has resulted in varied practices across states, with some companies offering quick prescriptions without adequate patient evaluation. Critics argue that this ease of access may lead to inappropriate prescriptions and insufficient follow-up care, potentially compromising patient safety.

New Diabetes Pill Offers Fat-Burning Benefits Without Muscle Loss

New Diabetes Pill Offers Fat-Burning Benefits Without Muscle Loss

Researchers at Karolinska Institutet and Stockholm University have developed a new pill that could revolutionize the treatment of type 2 diabetes and obesity. Unlike current GLP-1 medications such as Ozempic, which are administered via injection and work by suppressing appetite, this new treatment targets metabolism within skeletal muscle. The drug, a β2 agonist, is designed to activate signaling pathways that enhance muscle metabolism without overstimulating the heart. Early trials have shown that the pill can improve blood sugar regulation and body composition without the side effects commonly associated with GLP-1 therapies, such as appetite suppression and muscle loss. Initial human trials involving 48 healthy volunteers and 25 individuals with type 2 diabetes have shown promising results, with participants tolerating the treatment well.

Weight-loss drugs linked to lower breast cancer rates. What to know

Weight-loss drugs linked to lower breast cancer rates. What to know

A study of more than 110,000 women found those who took popular GLP-1 drugs prescribed for obesity or diabetes had a lower risk of breast cancer.